Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Estimated funding amount: $300,000 per award
Maximum project duration: 3 years
Support exploratory research projects focused on developing and validating technologies that improve the quality and handling of biospecimens used in cancer research.
Enhance research in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology.
Researchers and institutions involved in cancer research.
Cancer patients and the broader healthcare community.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments.
Non-domestic entities (foreign organizations) are also eligible to apply.
Open to U.S. and non-domestic (foreign) entities.
Projects must focus on advanced development and validation of emerging biospecimen science technologies.
Technologies should address unmet needs in cancer research and improve the quality of biospecimens.
Application budgets are limited to $300,000 per year in direct costs.
No cost-sharing is required.
Application due date: October 3, 2025.
Earliest submission date: March 4, 2025.
Applicants may submit more than one application, provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications under review at the same time.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
Applications will be evaluated based on scientific and technical merit, including significance, innovation, and approach.
Applications will undergo peer review and receive a written critique.
Funding decisions will be based on peer review outcomes and program relevance.
Priority will be given to projects that demonstrate innovative approaches to biospecimen science.
Projects must include quantitative performance measures to assess the success of the technology.
Applications proposing to use existing technologies without substantial further development will not be reviewed.
Projects should address cancer health disparities and propose solutions to mitigate them.
Innovative technologies with potential transformative impacts on cancer research will have a competitive edge.
Demonstrating the novelty and potential impact of the proposed technology.
Submitting applications that do not comply with the specific instructions outlined in the NOFO.
Engage with NIH contacts for clarification on eligibility and application requirements.
Highlight the unique aspects of the technology and its potential to address significant challenges in cancer research.